FOXM1、PLK1、HIF-1α及EZH2在乳腺癌中的表达及临床意义

Abstract
Figure/Table
References
Related Citation (11)

Download: PDF (2227 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To study the expressions and clinical significance of FOXM1, PLK1, HIF-1α and EZH2 in breast carcinoma.Methods Immunohistochemical staining was used not only to detect the expressions of FOXM1, PLK1, HIF-1α and EZH2 in 803 cases of invasive ductal breast carcinoma and para-tumor breast tissues, but also to evaluate the relationships between the expressions of FOXM1, PLK1, HIF-1α and EZH2 and the clinical pathological features of invasive ductal breast carcinoma, including the histological grade, lymph node metastasis and pTNM stage.Results Positive expression rates of FOXM1, PLK1, HIF-1α and EZH2 protein in invasive ductal breast carcinoma were 59.78%, 27.90%, 43.96% and 60.40% respectively, significantly higher than those in para-tumor breast tissues(29.89%, 0%, 3.86% and 20.92% respectively). There was a significant correlation between the expressions of FOXM1, PLK1, HIF-1α and EZH2 and the histopathological grade, lymph node metastasis and pTNM stage (P<0.05), but the expressions of FOXM1, PLK1, HIF-1α and EZH2 were not correlated with the patients’ age, menopause or tumor size. There was a significantly negative relationship between the expressions of PLK1, HIF-1α, EZH2 and ER. There was a significantly positive relationship between the expressions of Fox M1, EZH2 and HER-2 (P<0.01). The expressions of FOXM1, PLK1, HIF-1α and EZH2 in breast invasive ductal carcinoma were positively correlated(P<0.01).Conclusions The overexpressions of FOXM1, PLK1, HIF-1α and EZH2 may be involved in breast carcinogenesis and progression synergistically, and they might play an important role in the prognosis evaluation of breast carcinoma.

Key words： breast neoplasm FOMX1 PLK1 HIF-1α EZH2

Received: 15 January 2018

ZTFLH:

R365

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LIU Jing
	ZHOU Bingjuan
	MA Qiushuang
	CHEN Hong
	ZHANG Jinku

Cite this article:

LIU Jing,ZHOU Bingjuan,MA Qiushuang等. Expression and clinical significance of FOXM1, PLK1, HIF-1α and EZH2 in breast carcinoma[J]. Med. J. Chin. Peop. Armed Poli. Forc., 2018, 29(4): 353-357.

URL:

http://journal08.magtechjournal.com/Jwk_wjyx/EN/ OR http://journal08.magtechjournal.com/Jwk_wjyx/EN/Y2018/V29/I4/353

[1]	刘怡茜, 郭人花, 刘连科, 等. 叉头框转录因子M1在非小细胞癌中的表达及其与患者临床病理特征和生存的关系[J].中华肿瘤杂志, 2011, 33 (6): 426-430.
[2]	King S I, Purdie C A, Bray S E, et al. Immunohistochemical detection of Polo-like kinase-1 (PLK1) in primary breast cancer is associated with TP53 mutation and poor clinical outcome [J]. Breast Cancer Res, 2012, 14(2): R40.
[3]	Zhong H, De Marzo A M, Laughner E, et al. Overexpression of hypoxia-inducible factor- 1 alpha in common hum an cancers and their metastases [J]. Cancer Res, 1999, 59(22): 5830-5835.
[4]	汪小霞, 孟刚, 李丽, 等. 乳腺癌中EZH2和p53蛋白表达及其临床意义[J]. 临床与实验病理学杂志, 2015, 31(3): 273-276.
[5]	Halasi M, Gartel A L. FOX(M1) news—it is cancer [J]. Mol Cancer Ther, 2013, 12(3): 245-254.
[6]	Park H J, Gusarova G, Wang Z, et al. Deregulation of FoxM1b leads to tumour metastasis [J]. EMBO Mol Med, 2011, 3(1): 21-34.
[7]	Millour J, Constantinidou D, Stavropoulou A V, et al. FOXM1 is a transcriptional target of ERalpha and has a critical role in breast cancer endocrine sensitivity and resistance [J]. Oncogene, 2010, 29(20): 2983-2995.
[8]	Francis R E, Myatt S S, Krol J, et al. FoxM1 is a downstream target and marker of HER2 over expression in breast cancer [J]. Int J Oncol, 2009, 35(1): 57-68.
[9]	Wang G, Chen Q, Zhang X, et al. PCM1 recruits PLK1 to the pericentriolar matrix to promote primary cilia disassembly before mitotic entry [J]. J Cell Sci, 2013, 126(Pt6): 1355-1365.
[10]	Song B, Liu X S, Rice S J, et al. PLK1 phosphorylation of orc2 and hbo1 contributes to gemcitabine resistance in pancreatic cancer [J]. Mol Cancer Ther, 2013, 12(1): 58-68.
[11]	Zhang G, Zhang Z, Liu Z. Polo-like kinase 1 is overexpressed in renal cancer and participates in the proliferation and invasion of renal cancer cells [J]. Tumour Biol, 2013, 34(3): 1887-1894.
[12]	Maire V, Némati F, Richardson M, et al. Polo-like kinase 1: a potential therapeutic option in combination with conventional chemotherapy for the management of patients with triple-negative breast cancer [J]. Cancer Res, 2013, 73(2): 813-823.
[13]	Masoud G N, Li W. HIF-1α pathway: role, regulation and intervention for cancer therapy [J]. Acta Pharm Sin B, 2015, 5(5):378-389.
[14]	Cai F F, Xu C, Pan X, et al. Prognostic value of plasma levels of HIF-1a and PGC-1a in breast cancer [J]. Oncotarget, 2016, 7(47): 77793-77806.
[15]	车爱文, 陈淑苹, 康凯夫. EZH2和FHIT在肝癌中的表达及其临床意义[J]. 肿瘤学杂志, 2013, 19(7): 514-517.
[16]	Kim K H, Kim L, Choi S J, et al. The clinicopathological significance of epithelial mesenchymal transition associated protein expression in head and neck squamous cell carcinoma [J]. Korean J Pathol, 2014, 48(4): 263-269.
[17]	Ernst T, Chase A J, Score J, et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders [J]. Nat Genet, 2010, 42(8): 722-726.
[18]	Kleer C G, Cao Q, Varambally S, et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells [J]. Proc Natl Acad Sci U S A, 2003, 100(20): 11606-11611.
[19]	Knudsen E S, Dervishaj O, Kleer C G, et al. EZH2 and ALDH1 expression in ductal carcinoma in situ: complex association with recurrence and progression to invasive breast cancer [J]. Cell Cycle, 2013, 12(13): 2042-2050.
[20]	Myatt S S, Kongsema M, Man C W, et al. SUMOylation inhibits FOXM1 activity and delays mitotic transition [J]. Oncogene, 2014, 33(34): 4316-4329.
[21]	Fu Z, Malureanu L, Huang J, et al. Plk1-dependent phosphorylation of FOXM1 regulates a transcriptional programme required for mitotic progression [J]. Nat Cell Biol, 2008, 10(9): 1076-1082.
[22]	Mahara S, Lee P L, Feng M, et al. HIFI-α activation underlies a functional switch in the paradoxical role of Ezh2/PRC2 in breast cancer [J]. Proc Natl Acad Sci U S A, 2016, 113(26): E3735-E3744.
[23]	Cao P, Deng Z, Wan M, et al. MicroRNA-101 negatively regulates Ezh2 and its expression is modulated by androgen receptor and HIF-11alpha/HIF-1beta [J]. Mol Cancer, 2010, 9: 108.
[24]	Riquelme E, Suraokar M, Behrens C, et al. VEGF/VEGFR-2 upregulatesEZH2 expression in lung adenocarcinoma cells and EZH2 depletionenhances the response to platinum-based and VEGFR-2-targeted therapy [J]. Clin Cancer Res, 2014, 20(14): 3849-3861.
[25]	Geng J, Li X, Zhou Z, et al. EZH2 promotes tumor progression via regulating VEGF-A/AKT signaling in non-small cell lung cancer [J]. Cancer Lett, 2015, 359(2): 275-287.